Status:
UNKNOWN
Application of 68Ga-Pentixafor PET/CT for Thymoma
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Thymoma
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
Chemokine receptor CXCR4 was expressed in T cells and CXCR4-targeting molecular imaging- 68Ga-Pentixafor PET/CT could be a promising technique to evaluate the extent of thymoma with higher accuracy. T...
Detailed Description
Thymoma is 1 rare type of tumor developed on the thymic epithelium; patients with thymoma also might have myasthenia gravis (MG). Because of the scarcity and complexity of MG-associated thymoma, its p...
Eligibility Criteria
Inclusion
- suspected or confirmed untreated thymoma patients
- signed written consent.
Exclusion
- pregnancy
- breastfeeding
- known allergy against Pentixafor
- any medical condition that in the opinion of the investigator,may
- significantly interfere with study compliance.
Key Trial Info
Start Date :
June 22 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06086327
Start Date
June 22 2023
End Date
December 31 2024
Last Update
October 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospitall, Chinese Academy of Medical Science and Peking Union Medical College
Beijing, Beijing Municipality, China, 100730